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THERE is growing interest in the indi-
viduality of human tumours with respect
to cytotoxic drug sensitivity. That human
tumours differ in response to chemo-
therapy is well known; some diseases,
including choriocarcinoma and non-semi-
nomatous tumours of the testis, usually
respond well, in contrast, for example,
to adenocarcinomas and squamous carci-
nomas in various sites, that respond
poorly if at all. The question is, within
a well-defined category of tumour, how
wide is the range of drug sensitivity and
is there firm evidence that the best drug
to use may differ from one tumour to the
next? In other words, among what is
thought to be a group of otherwise identi-
cal tumours are there differences in the
spectrum of drug response? There is
widespread belief that such differences
do exist. The current wave of interest in
techniques by which the chemosensitivity
of individual tumours can be evaluated
(Salmon et al., 1978; Hamburger, 1981)
arises from the belief that individualizing
chemotherapy can achieve useful im-
provements in treatment. Studies on a
group of mouse colon tumours have also
given evidence for their chemotherapeutic
individuality (Double et al., 1975).
Our programme of work on the chemo-
therapeutic response of human tumours
grown as xenografts in immune-deprived
mice has given some evidence in support
of the individuality hypothesis. Nowak
et al. (1978) examined the response to
chemotherapy of 10 lines of colo-rectal
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carcinoma, evaluated by the growth-
delay endpoint. Response to the 8 drugs
that were used was generally poor, but
there was some evidence that the drugs
(melphalan, hexamethylmelamine and 5-
fluorouracil) that on average did best,
were not the best for every tumour.
Houghton & Houghton (1978) came to a
similar conclusion, also on colo-rectal
cancer. In a study of breast-cancer
xenografts, Bailey et al. (1980) examined
the response of 5 tumour lines to 6 single
agents and 2 drug combinations. Mel-
phalan alone, and the 2 combinations,
were on average the best treatments,
but among these the ranking varied from
one tumour line to the next. Bateman
et al. (1980) used in vitro drug sensitivity
tests to rank the response of 5 malignant
melanoma xenografts to each of 8 chemo-
therapeutic agents. Here again there was
a similar picture, with an overall trend
in drug ranking (in this case favouring
melphalan, MeCCNU and cis-platin) super-
imposed on which was some evidence for
individuality. In none of these studies
was the evidence for individuality statis-
tically significant, but it encouraged
further attempts to confirm this pheno-
menon.
The present work comprised a detailed
study on two pancreatic carcinoma xeno-
graft lines. The first, which we have called
HX32, was established by Pickard (1975).
It was used in the radiobiological study
described by Courtenay et al. (1976)
and is described in more detail by Courte-CHEMOSENSITIVITY OF PANCREATIC CARCINOMAS
nay & Mills (1978). The second xenograft
line (designated HX58) originated from
a peritoneal metastasis of an adeno-
carcinoma of the head of the pancreas
in a 51-year-old man. The 2 tumours
have a similar histological appearance,
consistent with derivation from the exo-
crine pancreas. The object of the study
was to determine the sensitivity of
these 2 tumours to 6 chemotherapeutic
agents. Clonogenic cell-survival curves
were determined following in vivo drug
administration, in order to obtain precise
estimates of cellular sensitivity.
The tumours were maintained by re-
peated passage in immune-suppressed
CBA mice. Following thymectomy at 4
weeks of age, mice were allowed to
recover for at least 2 weeks before being
given a whole-body dose of 9 Gy 60Co
y-radiation. Radiation death was pre-
vented by pretreating with 200 mg/kg
cytosine arabinoside i.p. 2 days before
irradiation. The latter technique obviates
the need for a marrow graft and slightly
improves receptivity to subsequent graft-
ing (Steel et al., 1978).
The present therapeutic studies were
performed on i.m. hind-leg tumours,
produced by injecting a suspension of
5 x 104 to 105 viable tumour cells. When
the tumours reached a diameter of 5-8
mm, drugs were given as single doses
injected i.p.
The drugs tested were vinblastine
sulphate (Eli Lilly); cis-dichloro-diam-
mino platinum II, (cis-platin, Johnson
Matthey); cyclophosphamide (CY, W. B.
Pharmaceuticals); melphalan (Burroughs
Wellcome); and hexamethyl melamine
(HMM). The latter drug was synthesized
at the Institute of Cancer Research, the
gift of Professor W. Ross. Methyl cyclo-
hexyl chloroethyl nitrosourea (MeCCNU)
and streptozotocin were supplied by the
National Cancer Institute. For injection
into the mice, MeCCNU and HMM were
dissolved in dimethyl sulphoxide, diluted
with 9 vol of Tween 80 and homogenized.
The remaining drugs were dissolved in
saline.
Tumours were excised for assay 16
to 18 h after treatment. This time was
chosen to ensure that drug action was
complete, and to allow time for repair
of any potentially lethal damage. None
of the drugs produced a noticeable drop
in cell yield in this time. Cell suspensions
were prepared from pooled tumours from
1-2 mice bearing 2 tumours each. The
suspensions were obtained by enzyme
treatment with collagenase and minimal
trypsinization. The cell suspensions, made
up in Ham's F12 medium with 15%
fetal bovine serum, were filtered through
a 30,um polyester mesh (Henry Simon,
Stockport). Small cell clusters passing
through the mesh were removed by
sedimentation at 4°C for 15 min. Appro-
priately diluted cell suspensions were set
up in replenishable soft-agar culture as
described by Courtenay & Mills (1978).
Tumour cells together with rat RBC
were suspended in 0-3% soft agar in
sterile test tubes in an atmosphere of
5% 02+5% C02+90% N2. Liquid med-
ium was added and changed weekly.
After 3-4 weeks the agar was decanted
onto a slide and colonies of more than 50
cells were counted under a dissecting
microscope. Plating efficiencies were 25-
40%. The surviving fraction was obtained
by dividing the PE of treated cells by
that of untreated controls. The data for
each drug were obtained from < 3 sepa-
rate experiments.
The results are shown in the Figure.
For each agent the maximum dose used
was approximately the single MTD. It is
thus possible to compare roughly the
log cell kill attainable with single doses
of each agent. The survival curves for the
most part are well defined, and in each
case are consistent with exponential
cell survival. This itself is interesting;
there is no evidence for sensitive and
resistant subpopulations of cells, and
this encourages attempts to use high-
dose chemotherapy in the clinic (Pritchard
et al., 1982). The levels of drug sensitivity
range widely, from streptozotocin which
produced no detectable cell kill in either
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FIGURE. Cell-survival curves for the 2 tumour lines treated with 6 chemotherapeutic agents:
HX32 (0), HX58 (0). In each case the dose scale extends up to the approximate LD1o dose
level (MTD).
xenograft line to melphalan which achie-
ved 3 decades of cell kill in each tumour
line at the MTD.
The remarkable feature of these data
is the evidence for identical sensitivity
to 4 of the drugs, but for a marked
difference in sensitivity to hexamethyl-
melamine. The data for cis-platin, mel-
phalan, MeCCNU, and streptozotocin are
indistinguishable between the 2 tumour
lines. Hexamethylmelamine, in contrast,
produced ov-er 2 decades of cell kill in
HX32 and barely detectable cell kill in
HX58. Cyclophosphamide was not very
effective in either of the tumours, but
there was evidence for systematically
greater effects in HX58.
In our view this is one of the clearest
demonstrations so far reported of signfi-
cant differences in spectrum of drug
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sensitivity between 2 very similar
xenograft lines of human cancer. The
similarity in sensitivity to the 4 drugs is
remarkable, as is the magnitude of the
difference in sensitivity to HMM. It would
seem that a small unidentified difference
must exist between the 2 tumours in
the way they incorporate or respond to
HMM.
Further work is required before it will
be possible to assess the potential bene-
fits ofindividualized cancer chemotherapy.
The view has strongly been expressed by
Salmon et al. (1980) that studies using
their direct soft-agar cloning assay have
demonstrated individuality in drug sensi-
tivity. We are not convinced by these
claims, partly because of technical inade-
quacies in the assay (Lancet, 1982) and
because it is impossible with only a
single specimen from each patient to
distinguish scatter in the data due to
technical factors from scatter that truly
reflects differences in chemosensitivity.
In contrast, each curve in the Figure
combines the results of 3-4 repeat experi-
ments on different passages of each
tumour line, and we therefore have some
confidence in claiming that the tumour
lines are similar in response to some
drugs and different in response to hexa-
methylmelamine.
It may well be that the results obtained
here illustrate 3 principles that could
apply more widely: the overall tendency
for some drugs to be generally much more
effective than others; a tendency for
tumours of the same type to show strong
similarity in response to most of the
agents available; and an element of
individuality which at times could be-
come therapeutically important.
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